NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Novo Nordisk is positioned as a global GLP-1 leader in obesity, while Structure Therapeutics is pursuing a different strategy as a clinical-stage challenger focused on oral obesity therapies. The article frames the divergence in approaches—injectable GLP-1 leadership versus development of oral candidates—rather than reporting any single new financial datapoint. Overall, it reads as strategic competitive positioning with limited immediate implications for near-term stock pricing.